Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Abstract

Lifirafenib is a novel inhibitor of key RAF family kinases and EGFR, with an acceptable risk-benefit profile and antitumor activity in patients with <i>B-RAF</i>^V600-mutated solid tumors, including melanoma, PTC, and LGSOC, as well as <i>K-RAS</i>-mutated NSCLC and endometrial carcinoma. Future comparisons with first-generation B-RAF inhibitors and exploration of lifirafenib alone or as combination therapy in patients with selected <i>RAS</i> mutations who are resistant/refractory to first-generation B-RAF inhibitors are warranted.